Aviado · Research
Longevity Daily
Friday, October 2, 2026
Listen
Today's Brief
The clearest human evidence yet that clearing senescent cells can modify age-related disease arrives in Nature Metabolism — a randomized controlled trial finding that dasatinib and quercetin reduce senescence markers in liver tissue, making it today's must-read. UK researchers also report that directly activating AMPK, the cellular energy switch, extended lifespan by 25%+ across three species, though a critical caveat applies. Sunnybrook scientists map the biological pathways tying menopause to brain aging, and trial data suggests low-dose rapamycin may improve cerebral blood flow in Alzheimer's gene carriers. Aviado unpacks why sage extract's LDL reductions are dramatic but its blood sugar effects depend heavily on your metabolic starting point.
10 stories6 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Brain Wiring Changes Can Distinguish Early Alzheimer's from Normal Aging Before Symptoms Appear
A new study identifies functional brain connectivity patterns that separate early Alzheimer's disease from the normal wear of aging — and the differences appear before any cognitive symptoms emerge. This kind of pre-symptomatic biomarker research is foundational for earlier intervention, when treatments have the greatest chance of working. If these connectivity signatures are validated in larger cohorts, they could become a standard part of cognitive health risk assessment.
Read more →Sunnybrook Scientists Uncover Biological Links Between Menopause and Brain Aging
Researchers at Sunnybrook Research Institute have identified biological mechanisms connecting the hormonal changes of menopause to accelerated brain aging — reframing menopause as a neurological inflection point, not just a reproductive one. The work adds to mounting evidence that the timing and management of menopause may meaningfully influence Alzheimer's and cognitive decline risk in women. For anyone in perimenopause or advising women in midlife, this underscores why brain health monitoring should begin well before cognitive symptoms appear.
Read more →Low-Dose Rapamycin Boosts Cerebral Blood Flow in Alzheimer's Gene Carriers
A small study (n=23) found that just 1 mg/day of rapamycin for four weeks increased cerebral blood flow in adults aged 45–65 who carry Alzheimer's genetic risk but show no symptoms yet. Reduced cerebral blood flow is an early marker of Alzheimer's progression, making this a potentially important — if preliminary — finding for those tracking rapamycin's neuroprotective potential. Keep the sample size firmly in mind: this needs replication in larger trials before drawing firm conclusions, but for APOE4 carriers already considering rapamycin, it adds a new brain health data point.
Read more →Supplements & Compounds
Sage Extract Cuts LDL by 35% in 3 Months — But Blood Sugar Results Are All Over the Map
New research reviewed by Aviado finds that 500 mg of standardized Salvia officinalis (sage) extract taken twice daily for 12 weeks can reduce LDL cholesterol by over a third — a drop comparable to low-dose statins. The catch: glucose response varies dramatically by individual, making sage a reliable tool for lipid management but an unreliable bet for blood sugar control unless you're closely tracking your own numbers. The key takeaway is personalization — if LDL is your primary concern and your metabolic health is otherwise intact, sage extract now has a validated dosing protocol behind it.
Read the full Aviado analysis →These 7 Supplements Actually Have Healthspan Research Behind Them
Super Age cuts through the supplement noise to spotlight seven compounds with genuine human evidence — including CoQ10 plus selenium, which cut cardiovascular death by 41% over four years in a Swedish study of adults aged 70–88, and 300 mg/day CoQ10 alone, which reduced all-cause mortality from 18% to 10% in a two-year heart failure trial. It's a useful calibration check for anyone who has been dosing based on trend rather than trial data. Not every compound will apply to your situation, but the specific numbers cited here are worth benchmarking against your current stack.
Read more →Research & Papers
Senolytics Dasatinib and Quercetin Pass a Human RCT — And the Results Matter for Longevity
The senolytic duo dasatinib and quercetin (D+Q) — arguably the most-followed anti-aging combination in the longevity community — just cleared a proof-of-principle randomized controlled trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), published in *Nature Metabolism*. The trial found that D+Q treatment meaningfully reduced cellular senescence markers in liver tissue, delivering the first controlled human evidence that clearing 'zombie cells' can modify a major age-related disease. MASH affects roughly 5% of the global population and is strongly linked to accelerated biological aging, making it a high-value disease target. This is the most clinically significant longevity finding of the week: senolytics are no longer just a mouse-study story.
Read more →A Drug That Directly Activates AMPK Extended Lifespan by 25%+ Across Three Different Species
Scientists from Queen Mary University of London and six partner institutions showed that Compound 991, a direct AMPK activator, extended lifespan by more than 25% in worms, flies, and zebrafish — confirming AMPK as a conserved longevity switch across divergent species. Mouse experiments showed signs of AMPK activation but no lifespan extension yet, and the lead researcher issued a blunt caveat: "Too much of the drug shortened life in our experiments. This is a switch that must be set correctly, not jammed on." Human applications remain distant, but the multi-species validation is a meaningful step for the geroprotector discovery pipeline.
Read more →Lifestyle & Nutrition
Walk More or Walk Faster — Either Way, You Live Longer
A new study highlighted by Harvard Health confirms that both walking distance and walking pace independently deliver longevity benefits — meaning you don't have to choose one over the other. This is useful news for anyone whose schedule or fitness level constrains one variable but not the other. Walking remains one of the most accessible and evidence-backed longevity interventions available, and this research adds flexibility to how you can make it count.
Read more →Insomnia Raises Stroke Risk by 26%, Meta-Analysis Finds
A new meta-analysis finds that insomnia is associated with a 26% higher risk of stroke — adding a serious cardiovascular consequence to the already long list of reasons to treat poor sleep as a medical issue, not a lifestyle inconvenience. Researchers noted substantial variation across the included studies, suggesting the magnitude of risk may differ by population and study design. But the directional signal is consistent: chronic insomnia belongs on your list of vascular risk factors to address proactively.
Read more →Industry & Policy
Generation Lab Is Staging a Biological Age Competition — And Recruiting Influencers to Test Its Drug Stack
MIT Technology Review reports that Generation Lab — the company behind researcher Yuancheng 'Ryan' Lu's celebrated partial reprogramming work — is staging a competition where participants race each other to achieve the greatest biological age reversal using its proprietary drug combination, which it claims can 'stop the spread of aging.' The contest actively targets influencers, gamifying what has previously been insider-only biohacking. Whether this is a genuine scientific signal or a commercially savvy PR play, it marks a visible shift in how longevity interventions are being packaged and brought to a mainstream audience.
Read more →